Nonetheless, Purinostat mesylate, a highly selective HDAC I/II binhibitor, 28 502 was demonstrated to outperform the pan-HDAC inhibitor panobinostat in MM [57]. Here, HDAC9 is linked to Miyoshi myopathy.